Breaking News Instant updates and real-time market news.

PFE

Pfizer

$35.79

-0.16 (-0.45%)

08:04
04/12/18
04/12
08:04
04/12/18
08:04

Pfizer initiates Phase 1b trial for DMD therapy candidate

Pfizer has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy, or DMD. The first boy received an infusion of the mini-dystrophin gene on March 22nd. Screening and enrollment of patients is expected to continue at up to four clinical research sites in the United States. Early data from this trial are expected in the first half of 2019, once all patients have been evaluated for one full year post-treatment. The multi-center, open-label, non-randomized, ascending dose study of a single intravenous infusion of PF-06939926 will enroll approximately 12 ambulatory boys aged 5 to 12 years with DMD. In addition to evaluating safety and tolerability, the study will evaluate measurements of dystrophin expression and distribution, as well as assessments of muscle strength, quality and function.

  • 24

    Apr

  • 25

    Apr

  • 08

    May

  • 05

    Jun

PFE Pfizer
$35.79

-0.16 (-0.45%)

04/05/18
LEHM
04/05/18
NO CHANGE
LEHM
Barclays upgrades Merck, downgrades Biogen and Pfizer in sector reassessment
Barclays analyst Geoff Meacham made some rating changes while reassessing the Biopharmaceutical sector. Biopharma sentiment has been negative since the start of 2018, despite a modest pick-up in deals and diminished rhetoric on drug pricing, Meacham tells investors in a research note titled "U.S. Biopharmaceuticals: Where to from here?" The analyst believes "more transformative" acquisitions, "clean" Phase 3 wins, and even a relatively strong Q1 earnings season could help "re-rate the sector" and get investors more engaged in the group. Ahead of the Q1 earnings season, Meacham upgraded Merck (MRK) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Biogen (BIIB), Pfizer (PFE), Biohaven Pharmaceutical (BHVN) and Myovant Sciences (MYOV). The analyst also lowered his price target for Equal Weight-rated AbbVie (ABBV) to $102 from $120, for Equal Weight-rated Amgen (AMGN) to $180 from $180, for Overweight-rated Prothena (PRTA) to $50 from $70 and for Overweight-rated Incyte (INCY) to $135 from $165.
04/05/18
04/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Hold from Buy at Stifel with analyst Kevin Cassidy citing the peaking server central processing unit cycle and valuation for the downgrade. 2. Johnson Controls (JCI) downgraded to Underperform from Sector Perform at RBC Capital with analyst Deane Dray citing the company's exposure to additional cash flow pressures in fiscal 2018, reduction in fiscal 2020 targets, and a market rotation toward "more defensive names." 3. Ryder (R) downgraded to Underweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he is making a "longer term call on 2019 expectations," which he believes are too high and embed "significant gains on residual values and used truck sales." 4. Ollie's Bargain Outlet (OLLI) downgraded to Neutral from Buy at BofA/Merrill with analyst Elizabeth Suzuki saying valuation is getting "richer," quarterly comps have been decelerating since 2015, and are now expected to be 1%-2% in 2018. 5. Biogen (BIIB), Pfizer (PFE), Biohaven (BHVN), and Myovant Sciences (MYOV) were downgraded to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.

TODAY'S FREE FLY STORIES

ETH

Ethan Allen

$19.04

-0.315 (-1.63%)

14:34
11/15/18
11/15
14:34
11/15/18
14:34
Hot Stocks
Ethan Allen design center set to open in the Superior Marketplace »

Ethan Allen has relocated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

Ziopharm

$2.95

0.27 (10.07%)

14:31
11/15/18
11/15
14:31
11/15/18
14:31
Upgrade
Ziopharm rating change  »

Ziopharm upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$56.36

0.06 (0.11%)

14:31
11/15/18
11/15
14:31
11/15/18
14:31
Technical Analysis
Technical Take: Papa John's spikes in last 5 minutes »

The shares have spiked to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

WFC

Wells Fargo

$52.69

0.54 (1.04%)

14:28
11/15/18
11/15
14:28
11/15/18
14:28
Periodicals
Wells Fargo to slash roughly 1,000 jobs in U.S., Reuters reports »

Wells Fargo said that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

CCO

Clear Channel Outdoor

$5.49

0.17 (3.20%)

, IHRT

iHeartMedia

$0.00

(0.00%)

14:27
11/15/18
11/15
14:27
11/15/18
14:27
Recommendations
Clear Channel Outdoor, iHeartMedia analyst commentary  »

Barrington says Clear…

CCO

Clear Channel Outdoor

$5.49

0.17 (3.20%)

IHRT

iHeartMedia

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$13.26

-0.36 (-2.64%)

14:20
11/15/18
11/15
14:20
11/15/18
14:20
Options
Large option blocks in Bed, Bath and Beyond as shares reach 52-week lows »

Large option blocks in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
11/15/18
11/15
14:20
11/15/18
14:20
General news
Canada manufacturing preview »

Canada manufacturing…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/15/18
11/15
14:17
11/15/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/15/18
11/15
14:16
11/15/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.19

0.69 (1.09%)

14:08
11/15/18
11/15
14:08
11/15/18
14:08
Hot Stocks
Citi reports October credit loss 2.63% vs. 2.42% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

DPZ

Domino's Pizza

14:04
11/15/18
11/15
14:04
11/15/18
14:04
Recommendations
Domino's Pizza analyst commentary  »

Stephens says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

ZIOP

Ziopharm

$2.85

0.17 (6.34%)

14:04
11/15/18
11/15
14:04
11/15/18
14:04
Upgrade
Ziopharm rating change  »

Ziopharm upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$129.48

0.715 (0.56%)

14:02
11/15/18
11/15
14:02
11/15/18
14:02
Hot Stocks
Motorola Solutions boosts quarterly dividend by 10% to 57c »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

FB

Facebook

$143.17

-1.08 (-0.75%)

13:58
11/15/18
11/15
13:58
11/15/18
13:58
Hot Stocks
Facebook board admits to pushing CEO, COO to 'move faster' on interference »

The board of Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SPY

SPDR S&P 500 ETF Trust

$271.90

1.71 (0.63%)

, SPX

S&P 500

$0.00

(0.00%)

13:57
11/15/18
11/15
13:57
11/15/18
13:57
Periodicals
U.S., China step up effort to strike G20 truce on trade, FT reports »

The U.S. and China have…

SPY

SPDR S&P 500 ETF Trust

$271.90

1.71 (0.63%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
11/15/18
11/15
13:55
11/15/18
13:55
General news
U.S. equities snapped back into the green »

U.S. equities snapped…

IAC

IAC

$180.83

0.23 (0.13%)

13:50
11/15/18
11/15
13:50
11/15/18
13:50
Hot Stocks
Rock Holdings acquires Dictionary.com, Thesaurus.com from IAC »

Dan Gilbert's Rock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$46.20

1.49 (3.33%)

13:48
11/15/18
11/15
13:48
11/15/18
13:48
Conference/Events
Fluor to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

RCMT

RCM Technologies

$4.03

0.03 (0.75%)

13:48
11/15/18
11/15
13:48
11/15/18
13:48
Hot Stocks
RCM Technologies announces acquisition of Thermal Kinetics, terms not disclosed »

RCM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARE

Ultragenyx

$51.33

2.92 (6.03%)

13:45
11/15/18
11/15
13:45
11/15/18
13:45
Conference/Events
Ultragenyx haqs a conference call hosted by JPMorgan »

JPMorgan Analyst Kasimov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

  • 27

    Nov

VIAB

Viacom

$31.87

0.07 (0.22%)

, VIA

Viacom

$35.23

-0.1 (-0.28%)

13:41
11/15/18
11/15
13:41
11/15/18
13:41
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VIAB

Viacom

$31.87

0.07 (0.22%)

VIA

Viacom

$35.23

-0.1 (-0.28%)

HP

Helmerich & Payne

$59.45

1.15 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 16

    Nov

  • 16

    Nov

  • 04

    Dec

NVDA

Nvidia

$201.85

4.63 (2.35%)

, AMAT

Applied Materials

$34.94

1.35 (4.02%)

13:41
11/15/18
11/15
13:41
11/15/18
13:41
Earnings
Notable companies reporting after market close »

Notable companies…

NVDA

Nvidia

$201.85

4.63 (2.35%)

AMAT

Applied Materials

$34.94

1.35 (4.02%)

POST

Post Holdings

$91.15

-0.43 (-0.47%)

WSM

Williams-Sonoma

$60.67

-1.09 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 16

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

PPL

PPL Corp.

$30.56

-1.63 (-5.06%)

13:35
11/15/18
11/15
13:35
11/15/18
13:35
Options
PPL Corp. put volume heavy and directionally bearish »

Bearish flow noted in PPL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$19.07

-6.59 (-25.68%)

13:32
11/15/18
11/15
13:32
11/15/18
13:32
Recommendations
PG&E analyst commentary  »

PG&E recent weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$25.48

-0.53 (-2.04%)

13:20
11/15/18
11/15
13:20
11/15/18
13:20
Hot Stocks
MSG Networks announces sponsorship deal for Devils broadcasts with William Hill »

MSG Networks and William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.